Nothing Special   »   [go: up one dir, main page]

AR050551A1 - Fenilaminotiazoles sustituidos y su uso - Google Patents

Fenilaminotiazoles sustituidos y su uso

Info

Publication number
AR050551A1
AR050551A1 ARP050103664A ARP050103664A AR050551A1 AR 050551 A1 AR050551 A1 AR 050551A1 AR P050103664 A ARP050103664 A AR P050103664A AR P050103664 A ARP050103664 A AR P050103664A AR 050551 A1 AR050551 A1 AR 050551A1
Authority
AR
Argentina
Prior art keywords
amino
alkyl
substituted
mono
alkoxy
Prior art date
Application number
ARP050103664A
Other languages
English (en)
Original Assignee
Bayer Healthcare Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Healthcare Ag filed Critical Bayer Healthcare Ag
Publication of AR050551A1 publication Critical patent/AR050551A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La presente solicitud se refiere a nuevos derivados de fenilaminotiazol, a procedimientos para su fabricacion, a su uso para el tratamiento y/o la profilxis de enfermedades, así como a su uso para la fabricacion de medicamentos para el tratamiento y/o la profilaxis de enfermedades, preferiblemente para el tratamiento y/o la prevencion de hipertension y otras enfermedades cardiovasculares. Reivindicacion 1: Compuesto de formula (1), en la que R1 representa hidrogeno o alquilo (C1-6), que puede estar sustituido con hidroxi, anino, mono- o dialquil (C1-4)amino, pirrolidino, piperidino, morfolino, piperazino o N'-metilpiperazino, R2 representa alquilo (C2-6), que está sustituido una o dos veces de forma igual o distinta con sustituyentes seleccionados del grupo de hidroxi, alcoxi (C1-4), amino, mono- y dialquil (C1-4)amino, R3 representa un sustituyente seleccionado del grupo de halogeno, ciano, nitro, alquilo (C1-6), hidroxi, alcoxi (C1-6), amino, mono- y di (C1- 6)alquilamino, carboxilo y alcoxi (C1-6)carbonilo, en la que alquilo y alcoxi pueden estar sustituidos a su vez respectivamente hasta cinco veces con fluor, y n representa el numero 0, 1, 2, 3, 4 o 5, en la que en el caso de que el sustituyente R3 aparezca varias veces, sus significados pueden ser iguales o distintos, así como sus sales, solvatos y solvatos de las sales.
ARP050103664A 2004-09-03 2005-09-01 Fenilaminotiazoles sustituidos y su uso AR050551A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE102004042607A DE102004042607A1 (de) 2004-09-03 2004-09-03 Substituierte Phenylaminothiazole und ihre Verwendung

Publications (1)

Publication Number Publication Date
AR050551A1 true AR050551A1 (es) 2006-11-01

Family

ID=35852458

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP050103664A AR050551A1 (es) 2004-09-03 2005-09-01 Fenilaminotiazoles sustituidos y su uso

Country Status (24)

Country Link
US (1) US8691850B2 (es)
EP (1) EP1812430B1 (es)
JP (1) JP4999691B2 (es)
KR (1) KR20070057235A (es)
CN (1) CN101056875A (es)
AR (1) AR050551A1 (es)
AT (1) ATE428710T1 (es)
AU (1) AU2005281941A1 (es)
BR (1) BRPI0514833A (es)
CA (1) CA2578596C (es)
DE (2) DE102004042607A1 (es)
EC (1) ECSP077296A (es)
ES (1) ES2324049T3 (es)
GT (1) GT200500238A (es)
IL (1) IL181670A0 (es)
MA (1) MA28869B1 (es)
MX (1) MX2007002470A (es)
NO (1) NO20071343L (es)
PE (1) PE20060589A1 (es)
SV (1) SV2006002218A (es)
TW (1) TW200621765A (es)
UY (1) UY29099A1 (es)
WO (1) WO2006027142A1 (es)
ZA (1) ZA200701820B (es)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102006009813A1 (de) * 2006-03-01 2007-09-06 Bayer Healthcare Ag Verwendung von A2b/A1 Rezeptor Agonisten zur Modulation der Lipidspiegel
DE102006042143A1 (de) * 2006-09-08 2008-03-27 Bayer Healthcare Aktiengesellschaft Neue substituierte Bipyridin-Derivate und ihre Verwendung
DE102006044696A1 (de) 2006-09-22 2008-03-27 Bayer Healthcare Ag 3-Cyano-5-thiazaheteroaryl-dihydropyridine und ihre Verwendung
DE102006056740A1 (de) 2006-12-01 2008-06-05 Bayer Healthcare Ag Cyclisch substituierte 3,5-Dicyano-2-thiopyridine und ihre Verwendung
DE102006056739A1 (de) 2006-12-01 2008-06-05 Bayer Healthcare Ag Substituierte 4-Amino-3,5-dicyano-2-thiopyridine und ihre Verwendung
DE102007035367A1 (de) 2007-07-27 2009-01-29 Bayer Healthcare Ag Substituierte Aryloxazole und ihre Verwendung
DE102007036076A1 (de) 2007-08-01 2009-02-05 Bayer Healthcare Aktiengesellschaft Dipeptoid-Produgs und ihre Verwendung
DE102007061764A1 (de) 2007-12-20 2009-06-25 Bayer Healthcare Ag Anellierte Cyanopyridine und ihre Verwendung
DE102007061763A1 (de) * 2007-12-20 2009-06-25 Bayer Healthcare Ag Substituierte azabicyclische Verbindungen und ihre Verwendung
DE102008008838A1 (de) 2008-02-13 2009-08-20 Bayer Healthcare Ag Cycloalkoxy-substituierte 4-Phenyl-3,5-dicyanopyridine und ihre Verwendung
DE102008013587A1 (de) * 2008-03-11 2009-09-17 Bayer Schering Pharma Aktiengesellschaft Heteroaryl-substituierte Dicyanopyridine und ihre Verwendung
ES2428818T3 (es) * 2008-05-29 2013-11-11 Bayer Intellectual Property Gmbh Dicianopiridinas sustituidas con 2-alcoxi y su uso
DE102008062567A1 (de) * 2008-12-16 2010-06-17 Bayer Schering Pharma Aktiengesellschaft Dipeptoid-Prodrugs und ihre Verwendung
DE102009006602A1 (de) * 2009-01-29 2010-08-05 Bayer Schering Pharma Aktiengesellschaft Alkylamino-substituierte Dicyanopyridine und deren Aminosäureester-Prodrugs
DE102009022894A1 (de) * 2009-05-27 2010-12-02 Bayer Schering Pharma Aktiengesellschaft Substituierte Piperidine
DE102010030688A1 (de) 2010-06-30 2012-01-05 Bayer Schering Pharma Aktiengesellschaft Substituierte Dicyanopyridine und ihre Verwendung
WO2015021358A2 (en) 2013-08-09 2015-02-12 Dominique Charmot Compounds and methods for inhibiting phosphate transport
WO2018153895A1 (de) 2017-02-22 2018-08-30 Bayer Pharma Aktiengesellschaft Selektive partielle adenosin a1 rezeptor-agonisten in kombination mit einem inhibitor der neutralen endopeptidase und/oder einem angiotensin ii rezeptor-antagonisten
WO2018153897A1 (de) 2017-02-22 2018-08-30 Bayer Pharma Aktiengesellschaft Selektive partielle adenosin a1 rezeptor-agonisten in kombination mit hcn-kanal-hemmern
WO2018153899A1 (de) 2017-02-22 2018-08-30 Bayer Pharma Aktiengesellschaft Selektive partielle adenosin a1 rezeptor-agonisten in kombination mit stimulatoren und/oder aktivatoren der löslichen guanylatcyclase (sgc)
WO2018153900A1 (de) 2017-02-22 2018-08-30 Bayer Aktiengesellschaft Selektive partielle adenosin a1 rezeptor-agonisten in kombination mit sglt-2-hemmern
WO2018153898A1 (de) 2017-02-22 2018-08-30 Bayer Pharma Aktiengesellschaft Selektive partielle adenosin a1 rezeptor-agonisten in kombination mit mineralocorticoid-rezeptor-antagonisten
JP7323913B2 (ja) * 2019-04-12 2023-08-09 国立大学法人 筑波大学 睡眠誘導剤である複素環化合物

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW299333B (es) 1992-12-29 1997-03-01 Takeda Pharm Industry Co Ltd
CN1056611C (zh) 1994-06-16 2000-09-20 美国辉瑞有限公司 吡唑并吡啶和吡咯并吡啶,其用途和用于制备它们的中间体
JPH09132529A (ja) 1995-11-09 1997-05-20 Ono Pharmaceut Co Ltd 一酸化窒素合成酵素阻害剤
AU727775B2 (en) 1996-01-17 2000-12-21 Novo Nordisk A/S Fused 1,2,4-thiadiazine and fused 1,4-thiazine derivatives, their preparation and use
JPH10324687A (ja) 1997-02-19 1998-12-08 Nippon Soda Co Ltd ピロール化合物、製法および農園芸用殺菌剤
WO1998054139A1 (de) 1997-05-30 1998-12-03 Basf Aktiengesellschaft Verfahren zur herstellung substituierter thiopyridine
CA2294830A1 (en) 1997-07-16 1999-01-28 John Bondo Hansen Fused 1,2,4-thiadiazine derivatives, their preparation and use
US6632823B1 (en) 1997-12-22 2003-10-14 Merck & Co., Inc. Substituted pyridine compounds useful as modulators of acetylcholine receptors
DE19834047A1 (de) 1998-07-29 2000-02-03 Bayer Ag Substituierte Pyrazolderivate
DE19834044A1 (de) 1998-07-29 2000-02-03 Bayer Ag Neue substituierte Pyrazolderivate
DE19943635A1 (de) 1999-09-13 2001-03-15 Bayer Ag Neuartige Aminodicarbonsäurederivate mit pharmazeutischen Eigenschaften
DE19943634A1 (de) 1999-09-13 2001-04-12 Bayer Ag Neuartige Dicarbonsäurederivate mit pharmazeutischen Eigenschaften
DE19943636A1 (de) 1999-09-13 2001-03-15 Bayer Ag Neuartige Dicarbonsäurederivate mit pharmazeutischen Eigenschaften
DE19947154A1 (de) 1999-10-01 2001-10-04 Bayer Ag Substituierte 2-Thio-3,5-dicyano-4-aryl-6-aminopyridine und ihre Verwendung
CA2398274C (en) 2000-02-25 2009-09-22 F. Hoffmann-La Roche Ag Adenosine receptor modulators
CA2415899A1 (en) 2000-07-18 2003-01-13 Chikashi Saitoh Medicine comprising dicyanopyridine derivative
AR031176A1 (es) 2000-11-22 2003-09-10 Bayer Ag Nuevos derivados de pirazolpiridina sustituidos con piridina
WO2002048115A2 (en) 2000-12-11 2002-06-20 E. I. Du Pont De Nemours And Company Quinazolinones and pyridinopyrimidinones for controlling invertebrate pests
HUP0303538A2 (hu) 2000-12-21 2005-02-28 Bristol-Myers Squibb Co. Tirozin kinázok Tec családjának tiazolil-vegyület inhibitorai és ezeket tartalmazó gyógyszerkészítmények
DE10110438A1 (de) 2001-03-05 2002-09-19 Bayer Ag Substituierte 2-Oxy-3,5-dicyano-4-aryl-6-aminopyridine und ihre Verwendung
DE10110750A1 (de) 2001-03-07 2002-09-12 Bayer Ag Neuartige Aminodicarbonsäurederivate mit pharmazeutischen Eigenschaften
DE10110749A1 (de) 2001-03-07 2002-09-12 Bayer Ag Substituierte Aminodicarbonsäurederivate
DE10110754A1 (de) 2001-03-07 2002-09-19 Bayer Ag Substituierte 2-Thio-3,5-dicyano-4-aryl-6-aminopyridine und ihre Verwendung
DE10110747A1 (de) 2001-03-07 2002-09-12 Bayer Ag Substituierte 2,6-Diamino-3,5-dicyano-4-aryl-pyridine und ihre Verwendung
DE10115922A1 (de) 2001-03-30 2002-10-10 Bayer Ag Cyclisch substituierte 2-Thio-3,5-dicyano-4-aryl-6-aminopyridine und ihre Verwendung
DE10115945A1 (de) 2001-03-30 2002-10-02 Bayer Ag Substituierte 2-Carba-3,5-dicyano-4-aryl-6-aminopyridine und ihre Verwendung
DE10134481A1 (de) * 2001-07-16 2003-01-30 Bayer Ag Substituierte 2-Thio-3,5-dicyano-4-phenyl-6-aminopyridine und ihre Verwendung
DE10238113A1 (de) * 2001-12-11 2003-06-18 Bayer Ag Substituierte 2-Thio-3,5-dicyano-4-phenyl-6-aminopyridine und ihre Verwendung
JP2003183254A (ja) 2001-12-20 2003-07-03 Yamanouchi Pharmaceut Co Ltd 2−アシルアミノ−3,5−ジシアノピリジン誘導体又はその塩
EP1506189A1 (en) 2002-04-26 2005-02-16 Vertex Pharmaceuticals Incorporated Pyrrole derivatives as inhibitors of erk2 and uses thereof
DE10220570A1 (de) 2002-05-08 2003-11-20 Bayer Ag Carbamat-substituierte Pyrazolopyridine
EP1388342A1 (en) 2002-08-07 2004-02-11 Aventis Pharma Deutschland GmbH Acylated, heteroaryl-condensed cycloalkenylamines and their use as pharmaceuticals
JP2006501217A (ja) 2002-08-12 2006-01-12 スージェン・インコーポレーテッド 新規キナーゼ阻害剤としての3−ピロリル−ピリドピラゾールおよび3−ピロリル−インダゾール
BR0317183A (pt) 2002-12-12 2005-11-01 Pharmacia Corp Método de usar compostos de aminocianopiridina como inibidores de proteìna quinase-2 ativada por proteìna quinase ativada por mitógeno
AR042667A1 (es) 2002-12-26 2005-06-29 Taisho Pharmaceutical Co Ltd Derivados de pirrolopirimidina y pirrolopiridina sustituidos con un grupo amino ciclico
TW200418829A (en) 2003-02-14 2004-10-01 Avanir Pharmaceutics Inhibitors of macrophage migration inhibitory factor and methods for identifying the same
AR045047A1 (es) 2003-07-11 2005-10-12 Arena Pharm Inc Derivados arilo y heteroarilo trisustituidos como moduladores del metabolismo y de la profilaxis y tratamiento de desordenes relacionados con los mismos
US7692017B2 (en) 2003-09-23 2010-04-06 Merck Sharp & Dohme Corp. Quinoline potassium channel inhibitors
US7338951B2 (en) 2003-11-10 2008-03-04 Synta Pharmaceuticals Corp. Pyridine compounds
US20050182105A1 (en) 2004-02-04 2005-08-18 Nirschl Alexandra A. Method of using 3-cyano-4-arylpyridine derivatives as modulators of androgen receptor function
JP2007161585A (ja) 2004-06-25 2007-06-28 Taisho Pharmaceut Co Ltd 環状アミノ基で置換されているピロロピリミジン及びピロロピリジン誘導体
DE102004032651A1 (de) 2004-07-06 2006-02-16 Bayer Healthcare Ag Verwendung von substituierten 2-Thio-3,5-dicyano-4-phenyl-6-aminopyriden bei der Behandlung von Übelkeit und Erbrechen
DE102006042143A1 (de) 2006-09-08 2008-03-27 Bayer Healthcare Aktiengesellschaft Neue substituierte Bipyridin-Derivate und ihre Verwendung
DE102006056739A1 (de) 2006-12-01 2008-06-05 Bayer Healthcare Ag Substituierte 4-Amino-3,5-dicyano-2-thiopyridine und ihre Verwendung
DE102006056740A1 (de) 2006-12-01 2008-06-05 Bayer Healthcare Ag Cyclisch substituierte 3,5-Dicyano-2-thiopyridine und ihre Verwendung
DE102007035367A1 (de) 2007-07-27 2009-01-29 Bayer Healthcare Ag Substituierte Aryloxazole und ihre Verwendung
DE102007036076A1 (de) 2007-08-01 2009-02-05 Bayer Healthcare Aktiengesellschaft Dipeptoid-Produgs und ihre Verwendung
DE102008013587A1 (de) 2008-03-11 2009-09-17 Bayer Schering Pharma Aktiengesellschaft Heteroaryl-substituierte Dicyanopyridine und ihre Verwendung
DE102008062567A1 (de) 2008-12-16 2010-06-17 Bayer Schering Pharma Aktiengesellschaft Dipeptoid-Prodrugs und ihre Verwendung
DE102009006602A1 (de) 2009-01-29 2010-08-05 Bayer Schering Pharma Aktiengesellschaft Alkylamino-substituierte Dicyanopyridine und deren Aminosäureester-Prodrugs

Also Published As

Publication number Publication date
US20080269300A1 (en) 2008-10-30
MA28869B1 (fr) 2007-09-03
UY29099A1 (es) 2006-04-28
NO20071343L (no) 2007-05-30
MX2007002470A (es) 2009-02-12
CA2578596A1 (en) 2006-03-16
TW200621765A (en) 2006-07-01
WO2006027142A1 (de) 2006-03-16
IL181670A0 (en) 2007-07-04
ATE428710T1 (de) 2009-05-15
US8691850B2 (en) 2014-04-08
GT200500238A (es) 2006-04-10
SV2006002218A (es) 2006-10-04
CA2578596C (en) 2012-10-23
ES2324049T3 (es) 2009-07-29
KR20070057235A (ko) 2007-06-04
EP1812430B1 (de) 2009-04-15
CN101056875A (zh) 2007-10-17
EP1812430A1 (de) 2007-08-01
PE20060589A1 (es) 2006-08-12
AU2005281941A1 (en) 2006-03-16
ECSP077296A (es) 2007-04-26
JP4999691B2 (ja) 2012-08-15
DE102004042607A1 (de) 2006-03-09
ZA200701820B (en) 2008-08-27
BRPI0514833A (pt) 2008-06-24
DE502005007106D1 (de) 2009-05-28
JP2008511614A (ja) 2008-04-17

Similar Documents

Publication Publication Date Title
AR050551A1 (es) Fenilaminotiazoles sustituidos y su uso
PE20131464A1 (es) Derivados de quinazolin-4 (3h)-ona utilizados como inhibidores de pi3 cinasa
ECSP099781A (es) Novedosos compuestos que son inhibidores de erk
MX2020003552A (es) Formas cristalinas.
NO20053775L (no) Diazepinoindol derivater som kinaseinhibitorer.
AR067646A1 (es) Ariloxazoles sustituidos y su uso
ECSP067100A (es) Preparación enantioselectiva del derivado de quinolina
DOP2005000011A (es) Derivados de indazol como inhibidores de la lipasa sensible a hormonas
ECSP109953A (es) Derivados de piridazinona
ECSP088598A (es) Derivados de piridazinona
UY29199A1 (es) Derivados tiazol, composiciones que los contienen, procedimientos de preparación y aplicaciones
UY27714A1 (es) 2 - heteroaril - pirimidinas inhibidoras de cdk, su preparación y su uso como medicamentos.
ECSP088550A (es) Nuevos compuestos que son inhibidores de erk
UY27742A1 (es) Derivados de quinazolina
ECSP066958A (es) Compuestos de morfolina
CY1109656T1 (el) Υποκατεστημενα παραγωγα μορφολινης και θειομορφολινης
DE60322359D1 (de) Imidazopyridinderivate als kinaseinhibitoren
AR088808A2 (es) Derivados de 2h-piridazin-3-ona, composiciones farmaceuticas que los contienen y un proceso para la preparacion de dichos derivados y el uso de dichos derivados para la preparacion de una composicion farmaceutica
AR053554A1 (es) Derivados de pirimidina para el tratamiento de trastornos hiperproliferativos
AR044078A1 (es) Dihidroquinazolinas sustituidas
PE20121471A1 (es) Derivados de sulfonamida heterociclicos utiles como inhibidores de mek
PE20140970A1 (es) Derivados de 6-ciclobutil-1,5-dihidro-pirazol [3,4-d) pirimidin-4-ona y su uso como inhibidores de pde9a
AR053347A1 (es) Derivados de [1,3]tiazolo[4,5-d]pirimidin-2(3h)-ona 5,7-sustituidos
AR078613A1 (es) Derivados de sulfoxidos benzooxazolicos y benzotriazolicos inhibidores de autotaxinas, medicamentos que los contienen y uso de los mismos para el tratamiento de tumores.
AR059320A1 (es) Composicion antitumorial que comprende un inhibidor de quinasas dependientes de ciclinas y un anticuerpo que inhibe un factor de crecimiento y/o un compuesto antimitotico

Legal Events

Date Code Title Description
FA Abandonment or withdrawal